{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:24:17Z","timestamp":1788535457628,"version":"build-2803163510"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Skaraborg Research and Development Council","award":["VGFOUSKB-989730"],"award-info":[{"award-number":["VGFOUSKB-989730"]}]},{"name":"Skaraborg Research and Development Council","award":["VGFOUSKB-997068"],"award-info":[{"award-number":["VGFOUSKB-997068"]}]},{"name":"Skaraborg Institute for Research and Development","award":["24\/1046"],"award-info":[{"award-number":["24\/1046"]}]},{"name":"Gothenburg Society of medicine","award":["GLS-999801"],"award-info":[{"award-number":["GLS-999801"]}]},{"DOI":"10.13039\/100030649","name":"Department of Emergency Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030649","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005754","name":"Sahlgrenska University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005754","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2023-02144"],"award-info":[{"award-number":["2023-02144"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003793","name":"Swedish Heart and Lung Foundation","doi-asserted-by":"publisher","award":["2021-0345"],"award-info":[{"award-number":["2021-0345"]}],"id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>With current, stricter lipid and blood pressure targets in patients with ischaemic heart disease (IHD), secondary prevention may be insufficient and vary between patient groups and primary health care centres (PHCCs). We assessed the heterogeneity of risk-factor control and secondary prevention using contemporary Swedish primary-care data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Cross-sectional study of IHD patients in September 2023 from QregPV, a Swedish regional primary-care register. We evaluated the proportions attaining risk-factor control [blood pressure &amp;lt;140\/90\u2005mmHg, LDL-cholesterol (LDL-C) &amp;lt; 1.4\u2005mmol\/L, and non-smoking] and the use of lipid-lowering therapy (LLT) and antithrombotic therapy (ATT) by age and sex using logistic regression models. Heterogeneity among PHCCs was estimated using multilevel models and summarized as adjusted median odds ratios (aMOR). Here 45 771 patients (34.5% women) were included. Combined risk-factor control was low, 15.5% (95% CI 15.0\u201316.0), mainly due to low LDL-C attainment, 20.7% (20.3\u201321.1). Combined risk-factor control decreased with higher age (P &amp;lt; 0.001) and was lower in women than in men, age-adjusted odds ratio (aOR) 0.60 (0.55\u20130.66). LLT and ATT were used by 77.2% (76.8\u201377.6) and 85.6% (85.2\u201385.9), with lower usage in women, aOR 0.52 (0.50\u20130.54) and aOR 0.58 (0.54\u20130.62). Substantial heterogeneity among PHCCs was observed, with combined risk-factor control aMOR 1.39 (1.32\u20131.48).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Combined risk-factor control was low, largely due to low LDL-C control, despite high LLT usage. Risk-factor control and the use of LLT and ATT varied between PHCCs and were lower in women than men. Concrete clinical strategies for attaining risk-factor goals in both sexes and for reducing PHCC variation are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwaf052","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T23:22:30Z","timestamp":1738797750000},"page":"1972-1982","source":"Crossref","is-referenced-by-count":6,"title":["Risk-factor control and secondary prevention in ischaemic heart disease in primary care: real-world insights from QregPV"],"prefix":"10.1093","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7771-7216","authenticated-orcid":false,"given":"Johan-Emil","family":"Bager","sequence":"first","affiliation":[{"name":"Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg , Medicinaregatan 3, 405 30 Gothenburg ,","place":["Sweden"]},{"name":"Department of Emergency Medicine, Sahlgrenska University Hospital , Bruna str\u00e5ket 15, 413 46 Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0147-8746","authenticated-orcid":false,"given":"Georgios","family":"Mourtzinis","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg , Medicinaregatan 3, 405 30 Gothenburg ,","place":["Sweden"]},{"name":"Department of Medicine, Geriatrics and Emergency Care M\u00f6lndal, Sahlgrenska University Hospital , G\u00f6teborgsv\u00e4gen 31, 431 80 M\u00f6lndal ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6534-2277","authenticated-orcid":false,"given":"Koen","family":"Simons","sequence":"additional","affiliation":[{"name":"Biostatistics, School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg , Box 469, 405 30 Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5409-6605","authenticated-orcid":false,"given":"Annika","family":"Rosengren","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg , Medicinaregatan 3, 405 30 Gothenburg ,","place":["Sweden"]},{"name":"Sahlgrenska University Hospital\/\u00d6stra , 416 85 Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0323-1061","authenticated-orcid":false,"given":"Maria","family":"\u00c5berg","sequence":"additional","affiliation":[{"name":"General Practice\/Family Medicine, School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg , Box 453, 405 30 Gothenburg ,","place":["Sweden"]},{"name":"Region V\u00e4stra G\u00f6taland, Regionh\u00e4lsan , Guldhedsgatan 5A, 413 20 Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1419-8460","authenticated-orcid":false,"given":"Tobias","family":"Andersson","sequence":"additional","affiliation":[{"name":"General Practice\/Family Medicine, School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg , Box 453, 405 30 Gothenburg ,","place":["Sweden"]},{"name":"Regionh\u00e4lsan R&D Centre, Skaraborg Primary Care , Regionens hus, 541 80 Sk\u00f6vde ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"key":"2026090410565330100_zwaf052-B1","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1161\/CIRCRESAHA.116.309115","article-title":"Decline in cardiovascular mortality: possible causes and implications","volume":"120","author":"Mensah","year":"2017","journal-title":"Circ Res"},{"key":"2026090410565330100_zwaf052-B2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2261-14-9","article-title":"Continuing decrease in coronary heart disease mortality in Sweden","volume":"14","author":"Berg","year":"2014","journal-title":"BMC Cardiovasc Disord"},{"key":"2026090410565330100_zwaf052-B3","doi-asserted-by":"crossref","first-page":"e005375","DOI":"10.1161\/CIRCOUTCOMES.118.005375","article-title":"Mortality from ischemic heart disease","volume":"12","author":"Nowbar","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026090410565330100_zwaf052-B4","author":"Socialstyrelsen"},{"key":"2026090410565330100_zwaf052-B5","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"2026090410565330100_zwaf052-B6","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jacc.2015.05.030","article-title":"Utilization of and adherence to guideline-recommended lipid-lowering therapy after acute coronary syndrome: opportunities for improvement","volume":"66","author":"Hirsh","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026090410565330100_zwaf052-B7","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1177\/2047487318825350","article-title":"Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry","volume":"26","author":"Kotseva","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"2026090410565330100_zwaf052-B8","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1177\/2047487314547652","article-title":"Geographical variations in the prevalence and management of cardiovascular risk factors in outpatients with CAD: data from the contemporary CLARIFY registry","volume":"22","author":"Ferrari","year":"2015","journal-title":"Eur J Prev Cardiol"},{"key":"2026090410565330100_zwaf052-B9","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1093\/eurjpc\/zwab014","article-title":"Gender gap in risk factor control of coronary patients: impossible to close?","volume":"29","author":"Lodi","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"2026090410565330100_zwaf052-B10","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1177\/2047487315585293","article-title":"Time trends and gender differences in prevention guideline adherence and outcome after myocardial infarction: data from the SWEDEHEART registry","volume":"23","author":"Hambraeus","year":"2016","journal-title":"Eur J Prev Cardiol"},{"key":"2026090410565330100_zwaf052-B11","doi-asserted-by":"crossref","first-page":"e014742","DOI":"10.1161\/JAHA.119.014742","article-title":"Sex differences in cardiovascular medication prescription in primary care: a systematic review and meta-analysis","volume":"9","author":"Zhao","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2026090410565330100_zwaf052-B12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2026090410565330100_zwaf052-B13","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/eurjpc\/zwab087","article-title":"Trends in blood pressure, blood lipids, and smoking from 259 753 patients with hypertension in a Swedish primary care register: results from QregPV","volume":"29","author":"Bager","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"2026090410565330100_zwaf052-B14","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/jech.57.5.347","article-title":"Care need Index, a useful tool for the distribution of primary health care resources","volume":"57","author":"Sundquist","year":"2003","journal-title":"J Epidemiol Community Health"},{"key":"2026090410565330100_zwaf052-B15","first-page":"53","article-title":"Ambulatory care groups: a categorization of diagnoses for research and management","volume":"26","author":"Starfield","year":"1991","journal-title":"Health Serv Res"},{"key":"2026090410565330100_zwaf052-B16","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/pds.1294","article-title":"The new Swedish prescribed drug register\u2013opportunities for pharmacoepidemiological research and experience from the first six months","volume":"16","author":"Wettermark","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026090410565330100_zwaf052-B17","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"2026090410565330100_zwaf052-B18","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"2026090410565330100_zwaf052-B19","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/jhh.2009.18","article-title":"Blood pressure recording bias during a period when the quality and outcomes framework was introduced","volume":"23","author":"Carey","year":"2009","journal-title":"J Hum Hypertens"},{"key":"2026090410565330100_zwaf052-B20","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/sim.7532","article-title":"Measures of clustering and heterogeneity in multilevel poisson regression analyses of rates\/count data","volume":"37","author":"Austin","year":"2018","journal-title":"Stat Med"},{"key":"2026090410565330100_zwaf052-B21","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1136\/jech.2004.029454","article-title":"A brief conceptual tutorial of multilevel analysis in social epidemiology: using measures of clustering in multilevel logistic regression to investigate contextual phenomena","volume":"60","author":"Merlo","year":"2006","journal-title":"J Epidemiol Community Health"},{"key":"2026090410565330100_zwaf052-B22","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2024"},{"key":"2026090410565330100_zwaf052-B23","volume-title":"RStudio: Integrated Development for R","author":"Posit team","year":"2023"},{"key":"2026090410565330100_zwaf052-B24","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1093\/eurheartj\/ehae558","article-title":"Variation in secondary prevention of coronary heart disease: the INTERASPIRE study","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"2026090410565330100_zwaf052-B25","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-Wide Cross-Sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"2026090410565330100_zwaf052-B26","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/eurjpc\/zwad389","article-title":"Long-term secondary prevention and outcome following acute coronary syndrome: real-world results from the Swedish primary care cardiovascular database","volume":"31","author":"Bentzel","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2026090410565330100_zwaf052-B27","doi-asserted-by":"crossref","first-page":"e036920","DOI":"10.1136\/bmjopen-2020-036920","article-title":"Adherence to lipid-lowering guidelines for secondary prevention and potential reduction in CVD events in Swedish primary care: a cross-sectional study","volume":"10","author":"\u00d6desj\u00f6","year":"2020","journal-title":"BMJ Open"},{"key":"2026090410565330100_zwaf052-B28","author":"SWEDEHEART"},{"key":"2026090410565330100_zwaf052-B29","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1177\/23969873231215629","article-title":"Long-term risk-factor control and secondary prevention are insufficient after first TIA: results from QregPV","volume":"9","author":"Bager","year":"2024","journal-title":"Eur Stroke J"},{"key":"2026090410565330100_zwaf052-B30","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"2026090410565330100_zwaf052-B31","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S0140-6736(21)00590-0","article-title":"Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis","volume":"397","author":"Blood Pressure Lowering Treatment Trialists Collaboration","year":"2021","journal-title":"Lancet"},{"key":"2026090410565330100_zwaf052-B32","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"2026090410565330100_zwaf052-B33","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41371-023-00801-5","article-title":"Hypertension: sex-related differences in drug treatment, prevalence and blood pressure control in primary care","volume":"37","author":"Bager","year":"2023","journal-title":"J Hum Hypertens"},{"key":"2026090410565330100_zwaf052-B34","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.3390\/ijerph16071165","article-title":"Cardiovascular disease and the female disadvantage","volume":"16","author":"Woodward","year":"2019","journal-title":"Int J Environ Res Public Health"},{"key":"2026090410565330100_zwaf052-B35","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1093\/eurheartj\/ehi397","article-title":"Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases","volume":"26","author":"Jochmann","year":"2005","journal-title":"Eur Heart J"},{"key":"2026090410565330100_zwaf052-B36","doi-asserted-by":"crossref","first-page":"e018271","DOI":"10.1136\/bmjopen-2017-018271","article-title":"Enhancing prescribing of guideline-recommended medications for ischaemic heart diseases: a systematic review and meta-analysis of interventions targeted at healthcare professionals","volume":"8","author":"Nguyen","year":"2018","journal-title":"BMJ Open"},{"key":"2026090410565330100_zwaf052-B37","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/eurheartj\/ehv641","article-title":"Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study","volume":"37","author":"Nielsen","year":"2016","journal-title":"Eur Heart J"},{"key":"2026090410565330100_zwaf052-B38","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"2026090410565330100_zwaf052-B39","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"2026090410565330100_zwaf052-B40","doi-asserted-by":"crossref","first-page":"100665","DOI":"10.1016\/j.lanepe.2023.100665","article-title":"Optimal implementation of the 2019 ESC\/EAS dyslipidaemia guidelines in patients with and without atherosclerotic cardiovascular disease across Europe: a simulation based on the DA VINCI study","volume":"31","author":"Brandts","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"2026090410565330100_zwaf052-B41","doi-asserted-by":"crossref","first-page":"e072953","DOI":"10.1136\/bmj-2022-072953","article-title":"Guidelines should consider clinicians\u2019 time needed to treat","volume":"380","author":"Johansson","year":"2023","journal-title":"BMJ"},{"key":"2026090410565330100_zwaf052-B42","doi-asserted-by":"crossref","first-page":"e004958","DOI":"10.1136\/bmjopen-2014-004958","article-title":"Smoker, ex-smoker or non-smoker? The validity of routinely recorded smoking status in UK primary care: a cross-sectional study","volume":"4","author":"Marston","year":"2014","journal-title":"BMJ Open"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwaf052\/61792940\/zwaf052.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/33\/11\/1972\/61792940\/zwaf052.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/33\/11\/1972\/61792940\/zwaf052.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T14:57:42Z","timestamp":1788533862000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/article\/33\/11\/1972\/8005254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":42,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,2,7]]},"published-print":{"date-parts":[[2026,9,4]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwaf052","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2025,2,7]]}}}